Los Angeles Capital Management LLC Chemo Centryx, Inc. Transaction History

Los Angeles Capital Management LLC

$24.7 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 05, 2021	SELL	$9.59 - $50.88 $109,326 - $580,032	-11,400 Closed	0 $0
Q1 2021 May 05, 2021	SELL	$49.53 - $68.4 $568,852 - $785,574	-11,485 Reduced 50.19%	11,400 $584,000
Q4 2020 Feb 04, 2021	BUY	$47.25 - $65.16 $150,727 - $207,860	3,190 Added 16.2%	22,885 $1.42 Million
Q3 2020 Nov 02, 2020	BUY	$46.35 - $61.69 $192,816 - $256,630	4,160 Added 26.78%	19,695 $1.08 Million
Q2 2020 Aug 05, 2020	SELL	$38.58 - $65.07 $5,787 - $9,760	-150 Reduced 0.96%	15,535 $893,000
Q1 2020 May 04, 2020	BUY	$32.73 - $50.78 $15,383 - $23,866	470 Added 3.09%	15,685 $630,000
Q4 2019 Feb 07, 2020	BUY	$6.81 - $39.55 $103,614 - $601,753	15,215 New	15,215 $602,000
Q3 2019 Nov 07, 2019	SELL	$6.47 - $8.96 $153,287 - $212,280	-23,692 Closed	0 $0
Q2 2019 Jul 29, 2019	BUY	$8.31 - $14.85 $15,955 - $28,512	1,920 Added 8.82%	23,692 $220,000
Q1 2019 Apr 25, 2019	BUY	$10.01 - $13.89 $27,427 - $38,058	2,740 Added 14.4%	21,772 $302,000
Q4 2018 Feb 11, 2019	SELL	$9.15 - $12.26 $44,835 - $60,074	-4,900 Reduced 20.47%	19,032 $208,000
Q2 2018 Jul 31, 2018	BUY	$10.62 - $13.98 $254,157 - $334,569	23,932 New	23,932 $315,000
Q1 2018 Apr 27, 2018	SELL	$5.9 - $14.99 $535,035 - $1.36 Million	-90,684 Closed	0 $0
Q4 2017 Feb 05, 2018	BUY	$5.53 - $8.42 $193,019 - $293,891	34,904 Added 62.57%	90,684 $540,000
Q3 2017 Nov 06, 2017	BUY	$6.5 - $10.69 $362,570 - $596,288	55,780	55,780 $414,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.